EPOCH-O regimen
Term · Oncology and biomedicine · MLC-T-ONC-013392
An immune-chemotherapy regimen consisting of etoposide, prednisone, vincristine (Oncovin), cyclophosphamide, doxorubicin (hydroxydaunorubicin) and ofatumumab, which may be used for the treatment of various aggressive non-Hodgkin lymphomas.
| Identifier | MLC-T-ONC-013392 |
|---|---|
| Field | Oncology and biomedicine |
| Abbreviation | EPOCH-O |
| Synonyms | O-EPOCH regimen; O-EPOCH; etoposide-prednisone-Oncovin-cyclophosphamide-hydroxydaunorubicin-ofatumumab regimen; EPOCH plus Arzerra; EPOCH plus ofatumumab; dose-adjusted EPOCH-ofatumumab; dose-adjusted etoposide-prednisone-vincristine-cyclophosphamide-ofatumumab; DA EPOCH-O; dose-adjusted etoposide/vincristine/doxorubicin/cyclophosphamide/prednisone plus ofatumumab regimen |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-013392",
"term": "EPOCH-O regimen",
"field": "Oncology and biomedicine",
"definition": "An immune-chemotherapy regimen consisting of etoposide, prednisone, vincristine (Oncovin), cyclophosphamide, doxorubicin (hydroxydaunorubicin) and ofatumumab, which may be used for the treatment of various aggressive non-Hodgkin lymphomas.",
"abbreviation": "EPOCH-O",
"synonyms": [
"O-EPOCH regimen",
"O-EPOCH",
"etoposide-prednisone-Oncovin-cyclophosphamide-hydroxydaunorubicin-ofatumumab regimen",
"EPOCH plus Arzerra",
"EPOCH plus ofatumumab",
"dose-adjusted EPOCH-ofatumumab",
"dose-adjusted etoposide-prednisone-vincristine-cyclophosphamide-ofatumumab",
"DA EPOCH-O",
"dose-adjusted etoposide/vincristine/doxorubicin/cyclophosphamide/prednisone plus ofatumumab regimen"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/epoch-o-regimen/"
}
Record 6,802 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.